From Single Nucleotide Polymorphisms to Constant Immunosuppression: Mesenchymal Stem Cell Therapy for Autoimmune Diseases

Raghavan Chinnadurai, Emory University
Edmund K Waller, Emory University
Jacques Galipeau, Emory University
Ajay Nooka, Emory University

Journal Title: BioMed Research International
Volume: Volume 2013
Publisher: Hindawi Publishing Corporation | 2013-11-19
Type of Work: Article | Final Publisher PDF
Publisher DOI: 10.1155/2013/929842
Permanent URL: http://pid.emory.edu/ark:/25593/fkx9n

Final published version: http://www.hindawi.com/journals/bmri/2013/929842/

Copyright information:
© 2013 Raghavan Chinnadurai et al. This is an Open Access work distributed under the terms of the Creative Commons Attribution 3.0 Unported License (http://creativecommons.org/licenses/by/3.0/).

Accessed November 28, 2018 11:29 PM EST
Review Article

From Single Nucleotide Polymorphisms to Constant Immunosuppression: Mesenchymal Stem Cell Therapy for Autoimmune Diseases

Raghavan Chinnadurai, 1 Edmund K. Waller, 1 Jacques Galipeau, 1,2 and Ajay K. Nooka 1

1 Department of Hematology and Oncology, Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA
2 Department of Pediatrics, Emory University, Atlanta, GA 30322, USA

Correspondence should be addressed to Ajay K. Nooka; anooka@emory.edu

Received 17 July 2013; Revised 20 September 2013; Accepted 20 September 2013

Academic Editor: Ken-ichi Isobe

Copyright © 2013 Raghavan Chinnadurai et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The regenerative abilities and the immunosuppressive properties of mesenchymal stromal cells (MSCs) make them potentially the ideal cellular product of choice for treatment of autoimmune and other immune mediated disorders. Although the usefulness of MSCs for therapeutic applications is in early phases, their potential clinical use remains of great interest. Current clinical evidence of use of MSCs from both autologous and allogeneic sources to treat autoimmune disorders confers conflicting clinical benefit outcomes. These varied results may possibly be due to MSC use across wide range of autoimmune disorders with clinical heterogeneity or due to variability of the cellular product. In the light of recent genome wide association studies (GWAS), linking predisposition of autoimmune diseases to single nucleotide polymorphisms (SNPs) in the susceptible genetic loci, the clinical relevance of MSCs possessing SNPs in the critical effector molecules of immunosuppression is largely undiscussed. It is of further interest in the allogeneic setting, where SNPs in the target pathway of MSC’s intervention may also modulate clinical outcome. In the present review, we have discussed the known critical SNPs predisposing to disease susceptibility in various autoimmune diseases and their significance in the immunomodulatory properties of MSCs.

1. Introduction

Mesenchymal stromal cells (MSCs) are under investigation in clinical trials to treat autoimmune disorders and degenerative disorders due to their immunomodulatory and regenerative properties. Various sources of MSCs have been described in the literature, but the one widely studied source is the bone marrow derived MSCs. MSCs in bone marrow represent 1 in 100,000 nucleated cells, but they play a significant role in regulating the niche for hematopoietic stem cells and immune homeostasis and hypothetically can differentiate into cartilage, bone, and adipocytes [1]. Major limitation for the use of MSCs in clinical trials is their low frequency in the bone marrow aspirates. This specific challenge has been addressed by MSC expansion into large quantities by virtue of their in vitro mitogenic properties under standard cell culture conditions [2]. This rapid expansion favors robust translational inquiry to utilize these cells in cellular therapy. To minimize ambiguity, the International Society for Cellular Therapy (ISCT) proposed minimal criteria to define human MSCs as expressing CD105, CD73, CD90 and lack of CD45, CD34, CD14 or CD11b, CD79α or CD19, and HLA-DR surface molecules [3].

The therapeutic potential of transfused MSCs was well demonstrated in animal models of experimental autoimmune encephalitis, diabetes, rheumatoid arthritis, myocardial infarction, acute lung injury, retinal degeneration, acute renal failure, transplant rejection, liver fibrosis, inflammatory bowel diseases, and graft versus host diseases [4, 5]. Based on these preclinical observations, therapeutic applications of MSCs are currently being explored in more than 300 clinical trials (http://www.clinicaltrials.gov/). MSCs were
used for the first time to treat grafts versus host disease (GVHD) and later to treat autoimmune disorders such as Crohn’s disease, multiple sclerosis, autoimmune rheumatic diseases, and autoimmune diabetes. The regenerative and anti-inflammatory properties eased their use to treat immune mediated disorders. MSCs suppress both innate and adaptive immune system as they inhibit the activation, proliferation, and also the function of lymphocytes, monocytes, dendritic cells, and natural killer cells. Previous reviews have already addressed the immunomodulatory properties of MSCs, and it is beyond the scope of current review [5–15].

The fundamental pathogenesis of autoimmune disorders lies on the loss of immune tolerance to self-antigens. In patients with autoimmune diseases, genetic changes in the genome of an individual affect the role of essential immunological pathways, leading to the breakdown of immune tolerance. The consequence of this effect is the inability of immune system to distinguish self- versus non-self-antigens. Genome wide association studies (GWAS) advanced the understanding of autoimmune diseases by identifying common single nucleotide polymorphisms (SNPs) and linking them to the cause of the diseases [16]. SNPs alter the phenotype and functionality of proteins in the immune system thereby affecting its function leading to disease. It is of essential interest to question the immunosuppressive properties of MSCs derived from the individuals bearing the disease causing SNPs.

Current clinical trials utilize MSCs obtained from autologous or allogeneic origin. In the autologous setting, MSCs acquired from the bone marrow of patients with autoimmune diseases are used in the suppressor therapy. While MSCs possess multiple immunoregulatory molecules to exert suppression, the question that remains unanswered is whether the SNPs in the immunomodulatory genes of MSCs affect the clinical outcome following MSC therapy. In the allogeneic setting, bone marrow-derived MSCs are expanded and banked from the universal healthy donor and subsequently administered to the patients. Since MSCs are derived from healthy donors, it is possible that these cellular products may not possess the genetic changes associated with the disease. However, MSCs specifically act on certain immune target pathways systemically or to the inflamed site and thereby execute immunosuppressive and regenerative functions. By considering the SNPs in these targets of MSC intervention, it raises the question if SNPs in the recipient’s immune pathway affect the clinical outcome. In the present review, we analyzed the common SNPs identified in the autoimmune diseases that are under investigation for MSC therapy and their significance in the mechanism of MSCs immunosuppressive effect and clinical outcome.

2. Multiple Sclerosis

Multiple sclerosis (MS) is an autoimmune disorder of the central nervous system where myelin and oligodendrocytes are targeted by cell mediated and humoral immunity [17]. The beneficial effects of MSC therapy have been well described in autoimmune encephalomyelitis (EAE) mouse model that provided a basis for further exploration in clinical trials [18–20]. Currently, close to 15 clinical trials are registered to use MSC therapy for the treatment of multiple sclerosis (http://www.clinicaltrials.gov/). MSCs have been well tolerated and were deemed safe in patients with MS in the early phase clinical trials. Mallam et al. described that MSCs derived from MS patients show expansion, differentiation, and surface marker expression similar to the MSCs from healthy individuals [21]. In contrast another study reported, although MSCs from MS patients exhibit normal growth, phenotype and immunomodulatory properties, they secrete higher levels of lipopolysaccharide-stimulated IP10 compared to MSC from healthy controls [22]. These contradictory results suggest the functional differences in the MSC populations, rooted from the changes in their genetic profile, isolated from MS patients. However, the efficacy results demonstrated the evidence of structural, functional, and physiological improvement and are suggestive of neuroprotection [23, 24]. The most relevant SNPs linked with the pathogenesis of MS are harbored in the genes HLADRB1, IL2RA, IL7R, CLEC16A, CD226, CYP27B1, MMEL1, SH2B3, CD40, CD80, CD86, and CD58 [25]. The relevance of IL2RA, IL7A, CYP27B1, SH2B3, and MMEL1 for MSC therapeutic activity is subtle. MSCs do not express CD40 [26]. CD80 and CD86 do not present on MSCs, and addition of IFNg does not upregulate these costimulatory molecules. Although HLADR is absent on the MSCs, IFNg upregulates its expression [27]. Considering the IFNg dependency of MSC’s suppressive activity, the current unknown factor is the differences in HLADR alleles on the immunosuppressive activity of MSCs. MSCs upregulate the adhesion molecule CD58 (lymphocyte function-associated antigen) after coculture with the T cells [28]. MSCs ability to bind to the inflamed tissues is important to execute their immunosuppressive effect [29]. The significance of SNPs on adhesion molecules on MSC’s engraftment potential requires further investigation.

3. Autoimmune Rheumatic Diseases

MSCs are under clinical investigation for the treatment of autoimmune rheumatic diseases such as rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), Sjögren’s syndrome, and systemic sclerosis. The animal models of collagen-induced arthritis reported varied results. Although an earlier study demonstrated that MSCs do not have any beneficial effect on mice with collagen-induced arthritis (CIA), subsequent studies demonstrated therapeutical effect [30–32]. Few other combination approaches were suggested such as conditioning of MSCs with the drugs such as bortezomib by modulating the microenvironment and thereby enhancing the therapeutic efficiency of MSCs [33]. Results of early phase ongoing clinical trials are not available to evaluate the clinical impact of MSCs in RA. Although a study suggested that stromal cell function is defective in patients with RA, another study demonstrated the immunosuppressive functions of MSCs derived from three RA patients [34, 35]. The common SNPs identified in RA and relevant to MSC biology and immunomodulation are in the genes of CD58 (adhesion molecule), IL6ST (CD130), and chemokine
investigations with the linkage to the genetic changes in the biology from autoimmune disease patients requires further specifically SNPs in MSC’s immunomodulatory properties [48]. Altogether MSC biology [47]. FAS/FASL interaction has been described in autophagy in the immunity and inflammation [56]. Defects Recent developments have highlighted a balancing role of cell compartments are recycled under stressful conditions. 55]. Autophagy is a cellular homeostatic process in which the in CD has identified a mutation in the genes of autophagy [54, 55]. Autophagy is a cellular homeostatic process in which the disease, is presumed alteration of genetic factors or gut microbiota or the host immune system [49]. Despite the etiology, all these factors share the common clinical manifestation of excessive intestinal inflammation. Clinical trials using MSCs as cell based inflammatory bowel suppressive therapy for CD are promising [50–53]. GWAS scan of nonsynonymous SNPs in CD has identified a mutation in the genes of autophagy [54, 55]. Autophagy is a cellular homeostatic process in which the cell compartments are recycled under stressful conditions. Recent developments have highlighted a balancing role of autophagy in the immunity and inflammation [56]. Defects

in this homeostatic autophagy process may cause the basic pathogenesis of many infectious and inflammatory diseases [56]. A majority of studies indicate that autophagy plays a major role in the CD pathogenesis [57–60]. ATG16L1 protein is an important player in the autophagy process by forming the autophagosomes. In the colitis mouse model, autophagy knockout mice (ATG16L1 deficient mouse) die after Dextran Sodium Sulfate (DSS) treatment due to the excessive production of proinflammatory cytokines IL-1 beta and IL-18 [61]. In addition, CD patients with T300A SNP in ATG16L1 gene show many abnormalities in the intestinal paneth cells, which are the producers of alpha-defensins in the intestine [62]. Peripheral blood mononuclear cells from the CD patients with T300A SNP in ATG16L1 gene secrete high levels of proinflammatory IL-1 beta and IL-6 upon in vitro stimulation [63]. Altogether these studies demonstrate the potential linkage between phenotype and SNPs in autophagy genes in CD patients. Two important studies describe the relevance of autophagy in MSC’s biological properties. The first study suggested that MSCs utilize autophagic mechanism to provide tumor stromal support [64]. The second study demonstrated the role of autophagy in MSC mediated hepatic regeneration in the animal model of liver diseases [65]. The role of autophagy in the MSC’s immunomodulatory properties and the significance of these SNPs in MSC’s biology is currently unknown. Utilization of autologous MSC treatment and the influence of SNPs in the genes of autophagy on the clinical outcome of crohn’s diseases require further investigation.

5. Autoimmune Diabetes

Type I diabetes results from the immune destruction of insulin producing beta cells in the pancreatic islets of Langerhans. Although transplantation of islets of Langerhans helps to maintain the insulin levels, immunosuppressive therapy is a requirement. MSCs are under clinical investigation to treat autoimmune diabetes due their immunosuppressive and angiogenic properties and the ability to regenerate beta cells [66]. Reversal of hyperglycemia with MSC therapy has been demonstrated in a number of diabetic animal studies [67–70]. Type I diabetes associated SNPs were reported in the genes such as IFIH1 (interferon-induced helicase), CTLA4, IL2RA, CLEC16A (C type lectin), and PTPN2 [71]. Of these genes, PTPN2 is of significant interest to the immunomodulatory properties of MSCs. PTPN2 regulate signaling events by dephosphorylating multiple JAK and STAT molecules, and MSCs immunosuppressive properties are highly depend on the signal induction through IFNγ [72]. Thus, the role of SNPs in PTPN2 gene on the suppressive properties of MSCs and IFNγ signaling events require further investigation.

6. Common SNPs in the Immunoregulatory Pathways of MSC’s Intervention

The unique feature of MSCs is their array of immunoregulators, which collectively mediate the immunosuppressive and regenerative functions that impact the clinical outcome. The
most important T cell regulators defined by MSCs are IDO and PDL1/PDL2-PD-1 pathways.

6.1. Indoleamine 2,3 Dioxygenase. Indoleamine 2,3 dioxygenase (IDO) is an enzyme of tryptophan degradation pathway which converts tryptophan to kynurenine and suppresses the T cell responses [73]. IFNγ upregulates IDO in MSCs thereby not only suppresses T cell proliferation but also induces the differentiation of monocytes into suppressor phenotype [74]. IDO expression by MSCs is considered as a standard readout for the functionality of the cellular product [75]. Impairment of IDO activity in the patients with autoimmune primary biliary cirrhosis has been reported, suggesting the possible role of IDO to maintain immune tolerance [76]. Arefayene et al. reported the genetic variants of IDO-1 gene with SNPs and associated altered enzyme activity, but this study does not include any disease specific SNPs in IDO [77]. A subsequent study demonstrated that SNP rs7820268 (C6202T) in the IDO gene is statistically more frequent in systemic sclerosis patients than in controls. In addition, patients bearing this SNP in IDO show impaired CD8+ T reg function [78]. This is an important functional study, which establishes a relationship of IDO SNPs with T cell responses. Future investigations are required to study the influence of SNPs in IDO on the immunomodulatory properties of MSCs.

6.2. PDL1/PDL2-PD-1 Pathway

6.2.1. T Cell Mediated Immune Responses. T cell activation is not only controlled by major histocompatibility complex (MHC) and T cell receptor (TCR) engagement but also by the interaction with other costimulatory molecules. PDL1/PDL2-PD-1 pathway is one such pathway which regulates the T cell tolerance in various conditions [79]. This pathway is implicated in negatively regulating T cell immunity in tumor microenvironment and chronic viral infections [80]. PD-1 is the receptor on the T cells with immunoreceptor tyrosine-based inhibiting motif (ITIM). Upon its engagement with the ligands PDL1 (B7H1) or PDL2 (B7DC), it provides negative signal to the T cells [81]. PDL1-PD1 pathway is implicated in MSC’s suppression of T cell proliferation upon licensing with proinflammatory cytokine IFNγ [20, 82–84]. Some studies reported that there is no correlation with SNPs in PDL1 gene and autoimmune diseases in Japanese patients. However, one study suggested that A/C polymorphism at position 8923 in PDL1 gene is associated with Graves diseases [85–87]. Similarly, another study demonstrated that SNPs in the gene for PDL2 is associated with SLE in Taiwan [88]. Since SNPs in the genes of PDL1 and PDL2 are not explicitly reported, it is possible to conclude that these ligands are intact on the surface of MSCs to execute the suppressive functions in the autologous therapy. However, the SNPs in the gene of PD-1 (PDCD1) are widely reported and associated with the autoimmune diseases [87]. Association between SNPs in PDCD1 and disease susceptibility to autoimmune diseases were demonstrated in SLE [89, 90], Type I diabetes [91], RA [92, 93], MS [94], and Graves disease [95]. Kroner et al. specifically showed the functional relevance of SNPs in PDCD1 polymorphism by demonstrating the deficit in PD-1 mediated inhibition of cytokine secretion in T cells from the multiple sclerosis patients [94]. These studies clearly suggest the role of dysfunctional PDL1/PDL2-PD-1 pathway in the autoimmune patients. In the allogeneic cellular therapeutic situation, although the ligands PDL1 and PDL2 on MSCs are intact, it is possible that the SNPs in PD-1 may compromise the delivery of negative signals to T cells. Hence, PDL1/PDL2 mediated therapeutic effect by allogenic or autologous MSCs may depend on the PD1 polymorphism of the recipient which could predict the treatment responsiveness.

6.2.2. Humoral Immune Responses. T helper cells and B cell interaction plays an important role in the breakdown of peripheral tolerance in the autoimmune disorders. The helper T cells that are not sensitive to self-tolerance mechanisms secrete proinflammatory cytokines, resulting in expansion of the autoreactive B cells which produce autoantibodies to cause the self damage [96]. MSCs also affect B cell differentiation into plasma cells and subsequent immunoglobulin production [97–100]. MSCs affect the plasma cell differentiation through contact independent pathway by cleaving CCL2 in a unique mechanism [101]. Additionally, there is data suggesting that MSCs suppress B cells through PDL1/PD1 pathway [102]. Another study by Liu et al. demonstrates that periodontal ligament stem cells inhibit B cell activation through PDL1/PD1 [103]. These results suggest that stem cells act on the humoral immune responses through the PDL1/PD1 pathway. PD-1 is upregulated on the B cells after stimulation with anti-IgM and PMA/ionomycin [104]. Bertias et al. reported that homozygous PD-1.3 SNP on the SLE patients causes lower expression of PD1 on CD19+ B cells [105]. It is possible to speculate that lower expression of PD-1 on B cells due to PD-1.3 SNP may compromise MSC’s inhibitory effect in B cells in SLE patients. Further studies are required to study the role of PD-1.3 SNP on the B cell interaction with MSCs.

7. Conclusion

MSCs are attractive to researchers due to their wide spectrum of immunomodulatory and regenerative properties, which collectively constitute their therapeutic activities. It is arguable that even if genetic changes such as SNPs affect one pathway, compensatory pathways may balance the functional machinery of MSCs. However, in certain situations, target pathways are crucial for the maintenance of immune tolerance, and in those conditions, MSCs could be considered as supplemental therapy along with the other immune suppressive molecules. SNPs are suggested as biomarkers for disease susceptibility in certain autoimmune disorders. Further studies are warranted in the direction of utilizing these SNPs as biomarkers for prediction of treatment responsiveness to MSC therapy.

References

M. Rafei, P. M. Campeau, A. Aguilar-Maehecha et al., “Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis by inhibiting CD4 Th17 T cells in a CC chemokine ligand 2-dependent manner,” *Journal of Immunology*, vol. 182, no. 10, pp. 5994–6002, 2009.


H. A. Papadaki, H. D. Kritikos, and C. Cemetsi, “Bone marrow progenitor cell reserve and function and stromal cell function are defective in rheumatoid arthritis: evidence for a tumor


Submit your manuscripts at http://www.hindawi.com